Duke Researchers Identify STK17B Kinase as Key Target for Overcoming Multiple Myeloma Drug Resistance
Key Insights
Duke University (search) researchers discovered that blocking the STK17B (search) enzyme reactivates ferroptosis (search), a natural cell death process, in multiple myeloma (search) cancer cells that had developed resistance to this mechanism.
The study published in Blood journal shows that STK17B (search) inhibition not only kills cancer cells directly but also enhances the effectiveness of existing multiple myeloma (search) therapies.
Preclinical testing in mouse models demonstrated significant tumor growth reduction using an oral STK17B inhibitor (search), with the team filing a provisional patent for potential commercialization.
Researchers at Duke University (search) have identified a critical enzyme that protects multiple myeloma (search) cancer cells from a natural form of cell death, opening a new therapeutic avenue for treating this incurable blood cancer. The study, published September 12 in the journal Blood, demonstrates that blocking the kinase STK17B (search) can reactivate ferroptosis (search)—an iron-dependent cell death mechanism—while simultaneously enhancing the effectiveness of current treatments.
STK17B: A Guardian Against Cancer Cell Death
Multiple myeloma (search) affects plasma cells (search), a type of white blood cell that normally produces antibodies to fight infection. In this cancer, malignant plasma cells accumulate in bone marrow, crowding out healthy blood-forming cells and producing abnormal antibodies. The disease accounts for nearly 10 percent of all blood cancer diagnoses, and while targeted treatments exist, drug resistance and symptom relapse remain significant challenges.
Professor Mikhail Nikiforov from Duke's Department of Pathology and Biomedical Engineering explained the paradox his team sought to understand: "Cancer cells live like there is no tomorrow. They accumulate iron at levels that would normally be toxic and tear cells apart, but that wasn't what we observed. Instead, these cancer cells adapted to resist the type of cell death triggered by iron overload."
The research team identified STK17B (search) as the key enzyme responsible for suppressing ferroptosis (search) in multiple myeloma (search) cells. Typically involved in cell death regulation and T-cell activation, STK17B maintains iron balance within cells by regulating pro- and anti-ferroptotic proteins. When ferroptosis functions normally, excess iron accumulation causes oxidative damage to cellular membranes, triggering cell death. However, multiple myeloma cells suppress this process, allowing them to survive despite toxic iron levels.
Clinical Significance and Patient Outcomes
The clinical relevance of STK17B (search) became apparent through patient data analysis. "Elevated levels of STK17B are associated with poor overall survival in MM patients," Nikiforov noted. "STK17B expression is also especially pronounced in relapsed cases of the disease, underscoring its role in therapy resistance."
This correlation between high STK17B (search) expression and poor prognosis, particularly in relapsed or refractory cases, positions the enzyme as both a prognostic marker and therapeutic target. The findings help explain why some multiple myeloma (search) patients develop resistance to treatment and experience disease relapse.
Therapeutic Breakthrough with STK17B Inhibition
Working with Timothy Willson, the Harold Kohn Distinguished Professor in Open Science Drug Discovery at the UNC Eshelman School of Pharmacy (search), the Duke team developed a compound capable of inhibiting STK17B (search)'s protective function. The inhibitor successfully reactivated ferroptosis (search) by disrupting the enzyme's control over iron buildup in cancer cells.
Beyond directly inducing cancer cell death, the STK17B inhibitor (search) demonstrated an additional benefit: it made multiple myeloma (search) cells more sensitive to conventional therapies. This dual mechanism—direct cytotoxicity and enhanced treatment sensitivity—addresses two critical challenges in multiple myeloma management.
Preclinical Validation and Future Development
The research team validated their findings using mouse models of multiple myeloma (search). Administration of an oral version of the STK17B inhibitor (search) produced encouraging results, both inducing ferroptosis (search) through increased iron uptake in cancer cells and significantly reducing tumor growth.
"These findings establish that STK17B (search) is a critical safeguard protecting MM cells from the toxic consequences of their iron independence," Nikiforov said. "Inhibiting this kinase holds much promise as a therapeutic strategy."
The team has filed a provisional patent based on their discoveries, with plans to eventually commercialize the therapy. They are also working to improve the compound's formulation and exploring its potential applications beyond multiple myeloma (search).
Broader Implications for Cancer Treatment
The research has implications extending beyond multiple myeloma (search). "Many other types of cancer cells are also resistant to ferroptosis (search)," Nikiforov observed. "We're curious to see how this inhibitor could improve therapies for other tumors outside of multiple myeloma."
This discovery represents a paradigm shift in understanding how cancer cells evade natural death mechanisms and suggests that targeting iron metabolism regulators could become a central strategy in cancer therapy. By dismantling the enhanced iron buffering systems that cancer cells exploit for survival, STK17B (search) inhibition fundamentally disrupts pathological iron equilibrium, leading to lethal oxidative stress within malignant cells.
The study received support from multiple National Institutes of Health grants, the National Cancer Institute, and the Paula and Rodger Riney Foundation, reflecting the significant scientific and clinical potential of this research approach.